Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics
ABSTRACT Human milk oligosaccharides (HMOs) may provide health benefits to infants partly by shaping the development of the early-life intestinal microbiota. In a randomized double-blinded controlled multicentric clinical trial, healthy term infants received either infant formula (control) or the sa...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9f2c1ad382d54614a4e9e4526f742cb3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9f2c1ad382d54614a4e9e4526f742cb3 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9f2c1ad382d54614a4e9e4526f742cb32021-11-15T15:57:02ZLinking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics10.1128/mBio.03196-192150-7511https://doaj.org/article/9f2c1ad382d54614a4e9e4526f742cb32020-04-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.03196-19https://doaj.org/toc/2150-7511ABSTRACT Human milk oligosaccharides (HMOs) may provide health benefits to infants partly by shaping the development of the early-life intestinal microbiota. In a randomized double-blinded controlled multicentric clinical trial, healthy term infants received either infant formula (control) or the same formula with two HMOs (2′-fucosyllactose and lacto-N-neotetraose; test) from enrollment (0 to 14 days) to 6 months. Then, all infants received the same follow-up formula without HMOs until 12 months of age. Breastfed infants (BF) served as a reference group. Stool microbiota at 3 and 12 months, analyzed by 16S rRNA gene sequencing, clustered into seven fecal community types (FCTs) with marked differences in total microbial abundances. Three of the four 12-month FCTs were likely precursors of the adult enterotypes. At 3 months, microbiota composition in the test group (n = 58) appeared closer to that of BF (n = 35) than control (n = 63) by microbiota alpha (within group) and beta (between groups) diversity analyses and distribution of FCTs. While bifidobacteriaceae dominated two FCTs, its abundance was significantly higher in one (FCT BiH for Bifidobacteriaceae at high abundance) than in the other (FCT Bi for Bifidobacteriaceae). HMO supplementation increased the number of infants with FCT BiH (predominant in BF) at the expense of FCT Bi (predominant in control). We explored the association of the FCTs with reported morbidities and medication use up to 12 months. Formula-fed infants with FCT BiH at 3 months were significantly less likely to require antibiotics during the first year than those with FCT Bi. Previously reported lower rates of infection-related medication use with HMOs may therefore be linked to gut microbiota community types. (This study has been registered at ClinicalTrials.gov under registration number NCT01715246.) IMPORTANCE Human milk is the sole and recommended nutrition for the newborn infant and contains one of the largest constituents of diverse oligosaccharides, dubbed human milk oligosaccharides (HMOs). Preclinical and clinical association studies indicate that HMOs have multiple physiological functions largely mediated through the establishment of the gut microbiome. Until recently, HMOs were not available to investigate their role in randomized controlled intervention trials. To our knowledge, this is the first report on the effects of 2 HMOs on establishing microbiota in newborn infants. We provide a detailed description of the microbiota changes observed upon feeding a formula with 2 HMOs in comparison to breastfed reference infants' microbiota. Then, we associate the microbiota to long-term health as assessed by prescribed antibiotic use.Bernard BergerNadine PortaFrancis FoataDominik GrathwohlMichèle DelleyDeborah MoineAline CharpagneLéa SiegwaldPatrick DescombesPhilippe AllietGiuseppe PuccioPhilippe SteenhoutAnnick MercenierNorbert SprengerAmerican Society for Microbiologyarticlehuman milk oligosaccharides2′FLLNnTinfantformulamicrobiotaMicrobiologyQR1-502ENmBio, Vol 11, Iss 2 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
human milk oligosaccharides 2′FL LNnT infant formula microbiota Microbiology QR1-502 |
| spellingShingle |
human milk oligosaccharides 2′FL LNnT infant formula microbiota Microbiology QR1-502 Bernard Berger Nadine Porta Francis Foata Dominik Grathwohl Michèle Delley Deborah Moine Aline Charpagne Léa Siegwald Patrick Descombes Philippe Alliet Giuseppe Puccio Philippe Steenhout Annick Mercenier Norbert Sprenger Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| description |
ABSTRACT Human milk oligosaccharides (HMOs) may provide health benefits to infants partly by shaping the development of the early-life intestinal microbiota. In a randomized double-blinded controlled multicentric clinical trial, healthy term infants received either infant formula (control) or the same formula with two HMOs (2′-fucosyllactose and lacto-N-neotetraose; test) from enrollment (0 to 14 days) to 6 months. Then, all infants received the same follow-up formula without HMOs until 12 months of age. Breastfed infants (BF) served as a reference group. Stool microbiota at 3 and 12 months, analyzed by 16S rRNA gene sequencing, clustered into seven fecal community types (FCTs) with marked differences in total microbial abundances. Three of the four 12-month FCTs were likely precursors of the adult enterotypes. At 3 months, microbiota composition in the test group (n = 58) appeared closer to that of BF (n = 35) than control (n = 63) by microbiota alpha (within group) and beta (between groups) diversity analyses and distribution of FCTs. While bifidobacteriaceae dominated two FCTs, its abundance was significantly higher in one (FCT BiH for Bifidobacteriaceae at high abundance) than in the other (FCT Bi for Bifidobacteriaceae). HMO supplementation increased the number of infants with FCT BiH (predominant in BF) at the expense of FCT Bi (predominant in control). We explored the association of the FCTs with reported morbidities and medication use up to 12 months. Formula-fed infants with FCT BiH at 3 months were significantly less likely to require antibiotics during the first year than those with FCT Bi. Previously reported lower rates of infection-related medication use with HMOs may therefore be linked to gut microbiota community types. (This study has been registered at ClinicalTrials.gov under registration number NCT01715246.) IMPORTANCE Human milk is the sole and recommended nutrition for the newborn infant and contains one of the largest constituents of diverse oligosaccharides, dubbed human milk oligosaccharides (HMOs). Preclinical and clinical association studies indicate that HMOs have multiple physiological functions largely mediated through the establishment of the gut microbiome. Until recently, HMOs were not available to investigate their role in randomized controlled intervention trials. To our knowledge, this is the first report on the effects of 2 HMOs on establishing microbiota in newborn infants. We provide a detailed description of the microbiota changes observed upon feeding a formula with 2 HMOs in comparison to breastfed reference infants' microbiota. Then, we associate the microbiota to long-term health as assessed by prescribed antibiotic use. |
| format |
article |
| author |
Bernard Berger Nadine Porta Francis Foata Dominik Grathwohl Michèle Delley Deborah Moine Aline Charpagne Léa Siegwald Patrick Descombes Philippe Alliet Giuseppe Puccio Philippe Steenhout Annick Mercenier Norbert Sprenger |
| author_facet |
Bernard Berger Nadine Porta Francis Foata Dominik Grathwohl Michèle Delley Deborah Moine Aline Charpagne Léa Siegwald Patrick Descombes Philippe Alliet Giuseppe Puccio Philippe Steenhout Annick Mercenier Norbert Sprenger |
| author_sort |
Bernard Berger |
| title |
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| title_short |
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| title_full |
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| title_fullStr |
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| title_full_unstemmed |
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics |
| title_sort |
linking human milk oligosaccharides, infant fecal community types, and later risk to require antibiotics |
| publisher |
American Society for Microbiology |
| publishDate |
2020 |
| url |
https://doaj.org/article/9f2c1ad382d54614a4e9e4526f742cb3 |
| work_keys_str_mv |
AT bernardberger linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT nadineporta linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT francisfoata linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT dominikgrathwohl linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT micheledelley linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT deborahmoine linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT alinecharpagne linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT leasiegwald linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT patrickdescombes linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT philippealliet linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT giuseppepuccio linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT philippesteenhout linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT annickmercenier linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics AT norbertsprenger linkinghumanmilkoligosaccharidesinfantfecalcommunitytypesandlaterrisktorequireantibiotics |
| _version_ |
1718427042108669952 |